Methylation Biomarker Panel for Esophageal Adenocarcinoma Risk Stratification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for surveillance of Barrett's esophagus are plagued by high inter-observer variability and limited predictive accuracy, leading to debates on the appropriate interval for endoscopic surveillance, and there is a need for effective biomarkers to stratify patients by their risk of neoplastic progression.

Innovation Solution

The use of hypermethylated promoter regions of specific genes, such as CDH13, TAC1, NELL1, AKAP12, SST, HPP1, p16, and RUNX3, to predict the risk of developing esophageal adenocarcinoma (EAC) or high-grade dysplasia (HGD) through methylation analysis, allowing for a tiered risk stratification model.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If endoscopic surveillance is performed at regular intervals for all Barrett's esophagus patients, then all patients are monitored for potential cancer development, but the low incidence rate (1/200 patient-years) makes this approach resource-intensive and costly

Engineering Contradiction:

Improvecancer detection reliabilityVSAvoidsurveillance resource consumption

Core Design Contradiction:

ReliabilityVSLoss of energy

Solution Approach 1:

The patient population is segmented into high-risk and low-risk groups based on methylation biomarker profiles. High-risk patients undergo intensive surveillance while low-risk patients receive reduced surveillance, eliminating the need for uniform monitoring of all patients and optimizing resource allocation.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The surveillance strategy changes from a uniform time-based interval to a risk-based approach using methylation levels as a parameter. Patients are monitored based on their molecular risk profile rather than their chronological age or diagnosis duration, allowing dynamic adjustment of surveillance intensity.

Inventive Principle:

Principle #35Parameter changes

2Loss of energy

If endoscopic surveillance intervals are extended to reduce costs, then resource consumption decreases, but cancers or advanced high-grade dysplasias may develop during the interim and be missed

Engineering Contradiction:

Improvesurveillance resource consumptionVSAvoidcancer detection reliability

Core Design Contradiction:

Loss of energyVSReliability

Solution Approach 1:

Methylation biomarker analysis is performed in advance to identify high-risk patients before cancer develops. This preliminary molecular assessment allows for proactive intensification of surveillance in patients most likely to progress, preventing missed diagnoses while extending intervals for low-risk patients.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The methylation biomarker profile provides continuous feedback on individual patient risk status. This molecular feedback loop allows dynamic adjustment of surveillance intervals based on each patient's actual risk level rather than following a fixed schedule, optimizing both detection reliability and resource efficiency.

Inventive Principle:

Principle #23Feedback

3Device complexity

If dysplasia is used as the current marker for EAC risk stratification, then a simple classification system is provided, but high inter-observer variability and limited predictive accuracy plague this approach

Engineering Contradiction:

Improverisk stratification system complexityVSAvoidrisk prediction accuracy

Core Design Contradiction:

Device complexityVSMeasurement precision

Solution Approach 1:

The mechanical/subjective assessment of dysplasia by pathologists is replaced with a molecular-based methylation analysis system. This substitution eliminates inter-observer variability inherent in histological assessment while providing more precise and objective risk prediction through quantifiable epigenetic markers.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The risk stratification system changes from using histological dysplasia grade as the parameter to using methylation levels of specific genes (CDH13, TAC1, NELL1, AKAP12, SST, HPP1, p16, RUNX3) as parameters. This molecular parameter set provides superior predictive accuracy while maintaining a manageable complexity through a defined panel of markers.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a rapid, accurate, and cost-effective method for stratifying patients into low, intermediate, and high-risk groups, reducing unnecessary surveillance for low-risk individuals and identifying high-risk patients for more frequent monitoring, thereby improving the detection of HGDs and EACs.

Implementation Method 1

Methylation constitutes the epigenetic modification of DNA by the addition of methyl groups, usually on cytosines at the sequence 5'-CpG-3'

Methodology Applied

Scientific EffectMethylation:

Data Source

PatentUS9758833B2Methods for predicting esophageal adenocarcinoma (EAC)

Publication Date: 2017.09.12 JOHNS HOPKINS UNIVERSITY

AI summary

This invention relates, e.g., to methods for predicting a subject's risk for developing esophageal adenocarcinoma (EAC) or high-grade dysplasia (HGD), comprising determining in a sample from the subject the methylation levels of transcriptional promoter regions of various combinations of, among other genes, (a) cadherin 13, H-cadherin (heart) (CDH13); (b) tachykinin-1 (TAC1); (c) nel-like 1 (NELL1); (d) A-kinase anchoring protein 12 (AKAP12); (e) somatostatin (SST); (f) transmembrane protein with EGF-like and two follistatin-like domains (HPP1); (g) CDKN2a, cyclin-dependent kinase inhibitor 2a (p16); or (h) runt-related transcription factor 3 (RUNX3).